EXHIBIT 10.1
[*] indicates that a confidential portion of the text of this agreement has
been omitted
SIXTH AMENDMENT TO LICENSE AGREEMENT
This Sixth Amendment to License Agreement (hereinafter "Amendment") is made
and effective on January 25, 2000, among XOMA TECHNOLOGY LTD., a company
organized and existing under the laws of Bermuda and having a place of business
at 0000 Xxxxxxx Xxxxxx, Xxxxxxxx, Xxxxxxxxxx 00000 and XOMA IRELAND LIMITED, a
company organized and existing under the laws of Ireland and having a place of
business at Xxxxxxx Xxxxxxx Xxxxx, Xxxxxxx, Xx. Xxxxx, Xxxxxxx (hereinafter
collectively referred to as "CORPORATION"), and NEW YORK UNIVERSITY, a
corporation organized and existing under the laws of the State of New York and
having a place of business at 00 Xxxxxxxxxx Xxxxxx Xxxxx, Xxx Xxxx, Xxx Xxxx
00000 (hereinafter "NYU").
WITNESSETH
WHEREAS, CORPORATION's predecessor in interest and NYU entered into a
certain agreement made and effective as of August 6, 1990, as amended and
restated on September 1, 1993 and as subsequently amended on August 1, 1996,
June 12, 1997, December 23, 1998 and June 25, 1999 (as so amended and restated,
the "Agreement"), pursuant to which, inter alia, CORPORATION's predecessor in
interest undertook to sponsor the
-2-
NYU Research Project (as such term is defined in the Agreement) and NYU granted
to CORPORATION's predecessor in interest the License (as such term is defined in
the Agreement); and
WHEREAS, CORPORATION and NYU wish to amend the Agreement as specified
herein;
NOW, THEREFORE, in consideration of the premises and the covenants,
conditions and promises set forth below, the parties hereto hereby agree as
follows:
1. Except as expressly provided for herein, all terms and conditions of
the Agreement shall remain in full force and effect.
2. Terms which are defined in the Agreement shall have the same meanings
when used in this Amendment, unless a different definition is given
herein.
3. The second clause (i.e., the language after the first semicolon) of
Subsection 7.c.(3) of the Agreement (after giving effect to the Fifth
Amendment thereto) shall be, and hereby is, amended by adding [*]
[*]
4. The proviso (i.e., the language after the first semicolon) in the last
sentence of Subsection 9.e. of the
-3-
Agreement (after giving effect to the Fifth Amendment thereto) shall
be, and hereby is, amended by adding "(1)" after the words "Products
for" and before the words "the mitigation" and by adding the following
language after the word "mammals" and before the words "in the event":
or (2) antibacterial and/or anti-endotoxin uses, in human clinical
indications (including, but not limited to, meningococcemia and future
indications but excluding periodontitis indications and ophthalmic
indications), in which the therapeutic action of the product involves
one or more of: (x) the binding and/or neutralization of
lipopolysaccharide or endotoxin which is on or released from gram
negative bacteria, thereby interrupting the inflammatory cascade
potentially leading to septicemia/sepsis, (y) killing of gram negative
or gram positive bacteria and (z) enhancing the ability of antibiotics
to kill gram negative or gram positive bacteria, including, but not
limited to, reversal of bacterial resistance to antibiotics,
5. This Amendment may be executed in one or more counterparts, each of
which shall be an original and all of which shall constitute together
the same document.
-4-
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as
follows:
NEW YORK UNIVERSITY XOMA TECHNOLOGY LTD.
By:____________________________________ By:_________________________________
Xxxxx X. Xxxxxxxx G. Xxxxx Xxxxxxxx
Vice Xxxxxxx Director
XOMA IRELAND LIMITED
SIGNED by
----------------------------
Xxxx Xxxx, Director,
duly authorized for and on behalf
of XOMA IRELAND LIMITED in the
presence of:
------------------------------
